PRITI PATEL, CRNP
Family Nurse Practitioner · KING OF PRUSSIA, PA
Individual Active NPI 1801515606
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 398 | 220,166 | $23,910,605 | $8,822,778 | $7,020,271 |
| 2023 | 224 | 69,846 | $8,612,021 | $2,991,702 | $2,382,080 |
| 2022 | 39 | 277 | $21,450 | $7,689 | $6,698 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J1306 | Injection, inclisiran, 1 mg | 50,836 | $12 | $9 |
| J2356 | Injection, tezepelumab-ekko, 1 mg | 18,900 | $18 | $14 |
| J3245 | Injection, tildrakizumab, 1 mg | 12,600 | $135 | $108 |
| J2350 | Injection, ocrelizumab, 1 mg | 11,400 | $59 | $47 |
| J2182 | Injection, mepolizumab, 1 mg | 7,200 | $30 | $24 |
| J2357 | Injection, omalizumab, 5 mg | 4,200 | $38 | $30 |
| J0517 | Injection, benralizumab, 1 mg | 2,850 | $165 | $131 |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 1,810 | $31 | $25 |
| 96372 | Injection of drug or substance under skin or into muscle | 731 | $12 | $10 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 585 | $0 | $0 |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | 189 | $113 | $89 |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 187 | $18 | $14 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Family Nurse Practitioner | 363LF0000X | ✓ | SP023680 | PA |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- No
Other Family Nurse Practitioner providers in Pennsylvania
- NPI 1205816261
- NPI 1801554308
- NPI 1700731072
- NPI 1366210098
- NPI 1952737660
- NPI 1538008156
- NPI 1376378216
- NPI 1235926866
See all Family Nurse Practitioner providers in Pennsylvania →
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.